Dobutamine is preferred over Dopamine in cardiogenic shock because of its effects related to
**Core Concept**
Dobutamine and dopamine are both catecholamines used in the treatment of cardiogenic shock. The primary difference between these two medications lies in their receptor selectivity and pharmacological effects.
**Why the Correct Answer is Right**
Dobutamine has a preferential action on beta-1 (β1) adrenergic receptors, which leads to increased contractility of the heart and a subsequent increase in cardiac output. This is particularly beneficial in cardiogenic shock where the heart's ability to pump blood is compromised. In contrast, dopamine has a more balanced action on dopamine (DA1) receptors, β1 receptors, and α1 receptors, which can lead to vasoconstriction and increased peripheral resistance. This can be counterproductive in cardiogenic shock where the goal is to improve cardiac output and reduce afterload.
**Why Each Wrong Option is Incorrect**
**Option A:** This option is incorrect because while dopamine does have some effect on β1 receptors, its action on other receptors (DA1 and α1) makes it less ideal for cardiogenic shock.
**Option B:** This option is incorrect because dobutamine's effect on β1 receptors is what makes it beneficial in cardiogenic shock, not its effect on α1 receptors, which would actually increase peripheral resistance.
**Option C:** This option is incorrect because while dopamine does have some effect on cardiac contractility, its action on other receptors (DA1 and α1) makes it less ideal for cardiogenic shock.
**Clinical Pearl / High-Yield Fact**
When choosing between dobutamine and dopamine in cardiogenic shock, remember that dobutamine's preferential action on β1 receptors makes it the preferred choice for improving cardiac output and reducing afterload.
**Correct Answer:** B. Its preferential action on β1 receptors.